News|Articles|September 15, 2025
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
Author(s)Marco Meglio
Avidity's del-zota shows promising results in reversing disease progression in Duchenne muscular dystrophy, paving the way for potential FDA approval.
Advertisement
Newly announced data from the EXPLORE44 (NCT05670730) and EXPLORE44-open label extension (OLE) trials showed that treatment with Avidity’s del-zota led to reversal of disease progression and improvements in a number of efficacy-related outcomes in patients with Duchenne muscular dystrophy (DMD) treated for up to 1 year. The company remains on track to submit a biologics license application (BLA) at the end of the year for accelerated approval.1
EXPLORE44 was a placebo-controlled, double-blind, phase 1/2 trial of 26 patients with DMD with mutations amenable to exon 44 skipping (DMD44). Of these, 17 directly enrolled into the EXPLORE44-OLE, where both ambulatory and non-ambulatory patients received 5 mg/kg of del-zota every 6 weeks over a 24-month period. While not all patients completed all the assessments, 1-year functional data from the pooled dosing cohorts for del-zota-treated patients showed improvement relative to DMD44 natural history cohorts.
Overall, patients on the investigational antisense oligonucleotide improved by 2.1 seconds on 4-Stair Climb whereas natural history cohorts declined by 2.7 seconds. Within the investigational group, the 10-Meter Walk/Run Test improved from baseline by 0.7 seconds compared with a 1.5-second decline in the natural history group (DMD44 Nat Hx N=22; del-zota n = 10) and Time to Rise from Floor improved from baseline by 3.2 seconds compared with a 1.6-second decline in the natural history group (DMD Nat Hx: n = 19; del-zota: n = 6).
"For the first time, we have data showing that sustained muscle protection leads to meaningful improvements across multiple key functional measures in DMD," Sarah Boyce, president and chief executive officer at Avidity, said in a statement. "These unprecedented data underscore the impact of our revolutionary targeted approach to deliver RNA directly to muscle."
Among the released data, findings showed stable North Star Ambulatory Assessment scores, whereas those in the natural history cohort declined by 2.4 points. In addition, patients on the investigational agent improved by 1.5 points on Performance of Upper Limb (PUL2) while natural history cohorts declined by 0.7 points. Notably, the improvements in PUL were similar across both ambulatory and non-ambulatory patients on treatment.
Boyce added, "We are acting with urgency to rapidly advance the del-zota development program and remain on track to submit a Biologics License Application (BLA) to FDA at year end 2025 for accelerated approval. We extend our deepest appreciation for the continued dedication of the investigators and their teams and, most importantly, the participants in our clinical trials and their families as we pursue a new treatment option for this relentless and devastating disease."
In the original double-blind period, trial participants on del-zota experienced significant increases of approximately 25% of normal dystrophin production and restored total dystrophin up to 58% normal. Creatine kinase (CK) levels were rapidly reduced by over 80% from baseline and sustained near normal for up to 16 months, with 50% of participants reaching normal CK levels at 1 year of treatment.
In August 2024, Avidity announced positive data from EXPLORE44 , showcasing del-zota’s impact on dystrophin production and CK changes. Among those treated with 5 mg/kg doses, investigators reported a statistically significant increase of 37% in exon 44 skipping in studied patients, which had DMD mutations amenable to exon 44 skipping. At 4 months, those in this lower dose group had a 66% exon 44 skipping and a greater than 80% reduction in CK levels relative to baseline.2
REFERENCES
1. Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44. News release. Avidity Biosciences. September 10, 2025. Accessed September 12, 2025. https://www.prnewswire.com/news-releases/avidity-biosciences-del-zota-demonstrated-reversal-of-disease-progression-across-key-functional-endpoints-in-explore44-and-explore44-ole-phase-12-trial-in-people-living-with-dmd44-302552339.html
2. Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial. News release. Avidity Biosciences. August 9, 2024. Accessed September 12, 2025. https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-aoc-1044-data-demonstrated-significant-increase-of-25-in-dystrophin-production-and-reduction-of-creatine-kinase-levels-to-near-normal-in-people-living-with-duchenne-muscular-dystrophy-amenab-302218647.html
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
2025 Women in Neurology Conference: Educating, Mentoring, and NetworkingSeptember 15th 2025
This Week on NeurologyLive® — September 15, 2025September 15th 2025
NeurologyLive® Brain Games: September 14, 2025September 14th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
3
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
4
This Week on NeurologyLive® — September 15, 2025
5
